A Long-Life, High-Rate Lithium/Sulfur Cell: A Multifaceted Approach to Enhancing Cell Performance

Lithium/sulfur (Li/S) cells are receiving significant attention as an alternative power source for zero-emission vehicles and advanced electronic devices due to the very high theoretical specific capacity (1675 mA·h/g) of the sulfur cathode. However, the poor cycle life and rate capability have remained a grand challenge, preventing the practical application of this attractive technology. Here, we report that a Li/S cell employing a cetyltrimethyl ammonium bromide (CTAB)-modified sulfur-graphene oxide (S-GO) nanocomposite cathode can be discharged at rates as high as 6C (1C = 1.675 A/g of sulfur) and charged at rates as high as 3C while still maintaining high specific capacity (~ 800 mA·h/g of sulfur at 6C), with a long cycle life exceeding 1500 cycles and an extremely low decay rate (0.039% per cycle), perhaps the best performance demonstrated so far for a Li/S cell. The initial estimated cell-level specific energy of our cell was ~ 500 W·h/kg, which is much higher than that of current Li-ion cells (~ 200 W·h/kg). Even after 1500 cycles, we demonstrate a very high specific capacity (~ 740 mA·h/g of sulfur), which corresponds to ~ 414 mA·h/g of electrode: still higher than state-of-the-art Li-ion cells. Moreover, these Li/S cells with lithium metal electrodes can be cycled with an excellent Coulombic efficiency of 96.3% after 1500 cycles, which was enabled by our new formulation of the ionic liquid-based electrolyte. The performance we demonstrate herein suggests that Li/S cells may already be suitable for high-power applications such as power tools. Li/S cells may now provide a substantial opportunity for the development of zero-emission vehicles with a driving range similar to that of gasoline vehicles

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

<span style="font-size:14.0pt;font-family:"Times New Roman";color:#090909;mso-bidi-font-weight: bold" lang="EN-IN">A facile <span style="font-size:14.0pt;font-family: "Times New Roman";color:#1B1B1B;mso-bidi-font-weight:bold" lang="EN-IN">synthesis of <span style="font-size:14.0pt;font-family:"Times New Roman";color:#090909; mso-bidi-font-weight:bold" lang="EN-IN">7,8/6,7 <span style="font-size: 14.0pt;font-family:"Times New Roman";color:#1B1B1B;mso-bidi-font-weight:bold" lang="EN-IN">fused <span style="font-size:14.0pt;font-family:"Times New Roman"; color:#090909;mso-bidi-font-weight:bold" lang="EN-IN">pyrano[<i><span style="font-size:14.0pt;font-family:Arial;color:#1B1B1B;mso-bidi-font-weight: bold" lang="EN-IN">4,3-b</span></i><span style="font-size:14.0pt;font-family: Arial;color:#1B1B1B;mso-bidi-font-weight:bold;mso-bidi-font-style:italic" lang="EN-IN">]<i> </i><span style="font-size:14.0pt;font-family:"Times New Roman";color:#090909; mso-bidi-font-weight:bold" lang="EN-IN">pyridinochromones <span style="font-size:14.0pt;font-family:"Times New Roman";color:#1B1B1B;mso-bidi-font-weight: bold" lang="EN-IN">and <span style="font-size:14.0pt;line-height:115%;font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman";color:#1B1B1B;mso-ansi-language:EN-IN; mso-fareast-language:EN-US;mso-bidi-language:HI;mso-bidi-font-weight:bold" lang="EN-IN">evaluation of antibacterial activity</span></span></span></span></span></span></span></span></span>

610-6137-Hydroxy-8/6-formyl chromones 2a-d on reaction with ethyl 3-aminocrotonate in acetic acid medium yield 7,8/6,7 fused pyrano[4,3-b]pyridino chromones 3a-d quantitatively.</span

Synthesis and antibacterial activity of 3-hydroxy-2(prop-1'-enyl)chromones

868-8703-Allyloxychromones 2a-d on refluxing in N,N-diethylaniline yield the corresponding abnormal Claisen rearrangement products 3-hydroxy-2-(prop-1'-enyl) chromones 3a-d

Synthesis of novel 8-[2-hydroxy-3-(alkylamino)propyl]-4-methoxy coumarins

805-810A series of new 8-[-2-hydroxy-3(alkylamino) propyl]-4-methoxy coumarins 7a-e, 8a-e have been synthesized from 3-allyl-2-hydroxy acetophenones 3a-e via key intermediate 8-(2-oxerane methyl)-4-methoxy coumarins 6a-e by regioselective opening of epoxide with alkyl amines

Synthesis and anti-microbial activity of new (1-alkyl-1H-1,2,3-triazol-4-yl)methyl-2H-chromene-3-carboxylates: A click chemistry approach

A series of new 1,4 disubstituted (1-alkyl-1H-1,2,3-triazol-4-yl)methyl-2H-chromene-3-carboxylates (4ai–4eiii) have been efficiently synthesized in moderate to excellent yields by the 1,3 dipolar cycloaddition between 2-propynyl-2H-chromene-3-carboxylates 3a–e and various alkyl azides under Cu(I) catalyzed conditions. The structures of the synthesized compounds are established based on IR, NMR, MASS Spectrometric methods and elemental analyses. The antibacterial and antifungal activities of synthesized compounds were evaluated. Compounds 4biii, 4ei, 4dii, 4ai, 4aii, 4bii showed good activity against bacterial strains and the compounds 4bi, 4eii against fungal strains